

EXHIBIT 1: Examples of Controlled Release Nanoparticulate Active Agent Dosage Forms Disclosed in U.S. Application No. 09/337,675 for “Controlled Release Nanoparticulate Compositions”

Example	Cite in Specification	Drug	Surface Stabilizer(s)	Amount of Spray Dried Drug/Surface Stabilizer Present in the Solid Dosage Form (w/w)	Excipient(s) Present in the Solid Dosage Form (w/w)	Dissolution Time of the Solid Dosage Form (in water)
2	Pages 24-25; Fig. 1	naproxen D90< 297 nm	polyvinyl-pyrrolidone (PVP)	29% (containing 93% naproxen and 7% PVP)	30% Klucel® HPC polymer 40% lactose 3% PVP 1% magnesium stearate	3 hours
4a	Page 26; Fig. 3	naproxen D90< 297 nm	polyvinyl-pyrrolidone (PVP)	39% (containing 93% naproxen and 7% PVP)	20% Klucel® HPC polymer 40% lactose 1% magnesium stearate	3-4 hours
4b	Page 26; Fig. 3	naproxen D90< 297 nm	polyvinyl-pyrrolidone (PVP)	39% (containing 93% naproxen and 7% PVP)	20% Shinetsu® L-HPC 40% lactose 1% magnesium stearate	1 hour
5a	Pages 26-27; Fig. 4	naproxen D90< 297 nm	polyvinyl-pyrrolidone (PVP)	39% (containing 93% naproxen and 7% PVP)	20% Methocel® K4M HPMC 40% lactose 1% magnesium stearate	40-50% dissolved in 12 hours
5b	Pages 26-27; Fig. 4	naproxen D90< 297 nm	polyvinyl-pyrrolidone (PVP)	39% (containing 93% naproxen and 7% PVP)	20% Methocel® E4M HPMC 40% lactose 1% magnesium stearate	3 hours
5c	Pages 26-27; Fig. 4	naproxen D90< 297 nm	polyvinyl-pyrrolidone (PVP)	39% (containing 93% naproxen and 7% PVP)	20% Methocel® K15M HPMC 40% lactose 1% magnesium stearate	40-50% dissolved in 12 hours
5d	Pages 26-27; Fig. 4	naproxen D90< 297 nm	polyvinyl-pyrrolidone (PVP)	39% (containing 93% naproxen and 7% PVP)	20% Methocel® K100M HPMC 40% lactose 1% magnesium stearate	40-50% dissolved in 12 hours
5e	Pages 26-27; Fig. 4	naproxen D90< 297 nm	polyvinyl-pyrrolidone (PVP)	39% (containing 93% naproxen and 7% PVP)	20% Methocel® K100LV HPMC 40% lactose 1% magnesium stearate	about 12-14 hours

EXHIBIT 1: Examples of Controlled Release Nanoparticulate Active Agent Dosage Forms Disclosed in U.S. Application No. 09/337,675 for “Controlled Release Nanoparticulate Compositions”

Example	Cite in Specification	Drug	Surface Stabilizer(s)	Amount of Spray Dried Drug/Surface Stabilizer Present in the Solid Dosage Form (w/w)	Excipient(s) Present in the Solid Dosage Form (w/w)	Dissolution Time of the Solid Dosage Form (in water)
5f	Pages 26-27; Fig. 4	naproxen D90< 297 nm	polyvinyl-pyrrolidone (PVP)	(containing 93% naproxen and 7% PVP) 39%	20% Methocel® E10M HPMC 40% lactose 1% magnesium stearate	about 12-14 hours
6a	Page 27; Fig. 5	naproxen D90< 297 nm	polyvinyl-pyrrolidone (PVP)	(containing 93% naproxen and 7% PVP) 29%	30% Klucel® HPC polymer 40% lactose 1% magnesium stearate	60 min.
6b	Page 27; Fig. 5	naproxen D90< 297 nm	polyvinyl-pyrrolidone (PVP)	(containing 93% naproxen and 7% PVP) 29%	30% Klucel® HPC polymer 35% lactose 1% magnesium stearate 5% Lubritab® (hydrogenated vegetable oil)	~100 min.
6c	Page 27; Fig. 5	naproxen D90< 297 nm	polyvinyl-pyrrolidone (PVP)	(containing 93% naproxen and 7% PVP) 29%	30% Klucel® HPC polymer 30% lactose 1% magnesium stearate 10% Lubritab® (hydrogenated vegetable oil)	~120 min.
6d	Page 27; Fig. 5	naproxen D90< 297 nm	polyvinyl-pyrrolidone (PVP)	(containing 93% naproxen and 7% PVP) 29%	30% Klucel® HPC polymer 20% lactose 1% magnesium stearate 20% Lubritab® (hydrogenated vegetable oil)	175 min.
7	Pages 27-28; Fig. 6	naproxen D90< 297 nm	polyvinyl-pyrrolidone (PVP)	(containing 93% naproxen and 7% PVP) 39%	20% Methocel® K100LV HPMC 20% lactose 1% magnesium stearate	13-14 hours
8a	Pages 28-29; Fig. 7	naproxen D90< 297 nm	polyvinyl-pyrrolidone (PVP)	(containing 93% naproxen and 7% PVP) 60%	5% Methocel® K100LV HPMC 40% lactose 1% magnesium stearate	50 min.
8b	Pages 28-29; Fig. 7	naproxen D90< 297 nm	polyvinyl-pyrrolidone (PVP)	(containing 93% naproxen and 7% PVP) 49%	10% Methocel® K100LV HPMC 40% lactose 1% magnesium stearate	350 min.

EXHIBIT 1: Examples of Controlled Release Nanoparticulate Active Agent Dosage Forms Disclosed in U.S. Application No. 09/337,675 for “Controlled Release Nanoparticulate Compositions”

Example	Cite in Specification	Drug	Surface Stabilizer(s)	Amount of Spray Dried Drug/Surface Stabilizer Present in the Solid Dosage Form (w/w)	Excipient(s) Present in the Solid Dosage Form (w/w)	Dissolution Time of the Solid Dosage Form (in water)
8c (duplicate of 7a)	Pages 28-29; Fig. 7	naproxen D90< 297 nm	polyvinyl-pyrrolidone (PVP)	39% (containing 93% naproxen and 7% PVP)	20% Methocel® K100LV HPMC 40% lactose 1% magnesium stearate	650 min.
9a	Page 29; Fig. 8	naproxen D90< 297 nm	polyvinyl-pyrrolidone (PVP)	39% (containing 93% naproxen and 7% PVP)	20% Klucel® HPC 40% lactose 1% magnesium stearate	~175 min. (tablets made via wet granulation)
9b	Page 29; Fig. 8	naproxen D90< 297 nm	polyvinyl-pyrrolidone (PVP)	39% (containing 93% naproxen and 7% PVP)	20% Methocel® HPMC 40% lactose 1% magnesium stearate	~600 min. (tablets made via wet granulation)
10	Page 30; Fig. 9	glipizide D90<276 nm	HPC-SL	1.7% (containing glipizide and HPC-SL in a ratio of 10:3)	32% Methocel® K100LV HPMC 64% lactose 1.6% magnesium stearate	16 hours
11	Pages 31-33	nifedipine D90<620 nm	HPC-SL	17.92% (containing 10 % nifedipine, 2 % HPC-SL, 10% mannitol, and 0.05% sodium lauryl sulfate)	30% Avicel PH102 30% Pharmatose DCL 20% Methocel K15M HPMC 1.2% colloidal silicon dioxide 0.86% magnesium stearate	22 hours
12	Pages 33-35; Fig. 10	nifedipine D90<620 nm	HPC-SL	17.92% (containing 10 % nifedipine, 2 % HPC-SL, 10% mannitol, and 0.05% sodium lauryl sulfate)	30% Avicel PH102 30% Pharmatose DCL 20% Methocel K15M HPMC 1.2% colloidal silicon dioxide 0.86% magnesium stearate + tablet coating consisting of Eudragit® L 12.5 talc dibutyl sebacate isopropyl alcohol	24 hours

EXHIBIT 1: Examples of Controlled Release Nanoparticulate Active Agent Dosage Forms Disclosed in U.S. Application No. 09/337,675 for “Controlled Release Nanoparticulate Compositions”

Example	Cite in Specification	Drug	Surface Stabilizer(s)	Amount of Spray Dried Drug/Surface Stabilizer Present in the Solid Dosage Form (w/w)	Excipient(s) Present in the Solid Dosage Form (w/w)	Dissolution Time of the Solid Dosage Form (in water)
13	Pages 35-37	glipizide D90<650 nm	HPC-SL	3.36% (containing 10 % glipizide, 3 % HPC-SL, 15% mannitol)	35.8% Avicel™ pH101 60% Methocel K100LV HPMC 0.4% Aerosil™ 200 0.5% magnesium stearate	22+ hours